healthcare

Why This Anthrax Vaccine Study Is Getting a New Cash Injection

Altimmune Inc. (NASDAQ: ALT) shares jumped on Wednesday after the company announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with ...
Read Full Story »

4 Biotechs Making Major Moves on Tuesday

Tuesday was a breakout day for a few biotech companies that saw either huge gains or massive losses. With the markets holding near all-time highs, these companies could move the ...
Read Full Story »

Meet the FDA’s Newest Fast Tracked Zika Virus Treatment

Moderna, Inc. (NASDAQ: MRNA) shares jumped late on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika ...
Read Full Story »

Why the FDA Is a Little Slow on This Jet Lag Study

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares dropped early to begin the week after the firm announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug ...
Read Full Story »

Good News for Stem Cell Transplants

Akari Therapeutics PLC (NASDAQ: AKTX) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its stem cell ...
Read Full Story »

Tilray’s Q2: A Swing and a Miss

Tilray Inc. (NASDAQ: TLRY) released second-quarter financial results after markets closed Tuesday. The company said that it had a net loss of $0.36 per share and $45.9 million in revenue, ...
Read Full Story »

Huge Plaque Psoriasis Breakthrough at Eli Lilly

Eli Lilly and Co. (NYSE: LLY) shares made a handy gain on Tuesday after the firm announced results from its late-stage study for the treatment of moderate to severe plaque ...
Read Full Story »

Breakthrough Gastrointestinal Tumor Therapy Reaches New Milestone

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) shares nearly doubled on Tuesday after the firm announced top-line results from its late-stage trial treating patients with gastrointestinal stromal tumors (GIST). Specifically, this data ...
Read Full Story »

What to Expect When Tilray Reports on Tuesday

Tilray Inc. (NASDAQ: TLRY) is scheduled to release its second-quarter financial results after the markets close on Tuesday. The consensus estimates are calling for a net loss of $0.25 per ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Cannabis Stocks

Cannabis stocks had a huge showing on Wall Street last fall. In fact, most of the news flow surrounding these stocks had investors pouring money into them. Some of the ...
Read Full Story »

Short Sellers Make a Move on Big Biotechs

The short interest data are out for the most recent settlement date, July 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Major Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Is Amarin’s Cardio Trial in Trouble?

Amarin Corp. PLC (NASDAQ: AMRN) shares dropped on Friday after the firm announced that it received notice from the U.S. Food and Drug Administration (FDA). According to the notice, the ...
Read Full Story »

Revolutionary Peanut Allergy Treatment Is One Step Closer

Shares of DBV Technologies S.A. (NASDAQ: DBVT) shot up on Thursday after the company announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration ...
Read Full Story »

What These Late-Stage Obesity Studies Could Mean for the Future of Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) shares jumped on Wednesday after the company announced positive results from two of its late-stage obesity clinical trials. Specifically, the data come from two Phase ...
Read Full Story »